Fibrinogen degradation products in plasma following induced hyperfibrinolysis.
OBJECTIVE
To detect fibrinogen degradation products (FDP) in blood as a result of induced hyperfibrinolysis.


METHODS
This in-vitro and in-vivo study compared the relationship between the plasma FDP levels, the rate of their production, the degree of fibrinolysis and the effect of protease inhibitors in primary hyperfibrinolysis conditions.


METHODS
Department of Medical Biochemistry, Kharkov General and Emergency Operational and Research Institute, Ukraine in collaboration with the Department of Biochemistry, University of Nairobi, Kenya.


METHODS
Blood plasma of humans and rabbits.


METHODS
Streptokinase was added to plasma of humans and rabbits to induce in vitro primary hyperfibrinolysis. Studies on the activity of plasmin by protamine degradation was conducted with this streptokinase treated plasma. The effect of natural protease inhibitors of rabbit fibrinolysis were also conducted by adding each inhibitor to the streptokinase treated blood plasma. A further study on FDP levels in experimental rabbits with primary hyperfibrinolysis, was conducted by giving the animals intramuscular injections of pantripin.


RESULTS
In vivo studies with rabbits show a correlation between the degree of fibronolysis and the inhibitory effect of natural inhibitors of fibrinolysis. Increased FDP levels were recorded following hyperfibrinolysis. Natural inhibitors of fibrinolysis decrease FDP levels in experimental samples.


CONCLUSIONS
These results suggest the possibility of applying plasmin inhibitors during pathological conditions of hyperfibrinolysis.
Chek
J B
JB
Department of Biochemistry, University of Nairobi, P.O. Box 30197, Nairobi.
Panchenko
N I
NI
D000818:Animals; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D011480:Protease Inhibitors / Q000494:pharmacology; D011817:Rabbits; D013300:Streptokinase / Q000494:pharmacology*
D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D011480:Protease Inhibitors; D013300:Streptokinase